A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC
A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC
Active, not recruiting · NCT05319431 · Registry updated 2025-03-12Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC | Unresectable, Non-metastatic Hepatocellular Carcinoma | Active, not recruiting | Phase 2 | 2025-03-12 | NCT05319431 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Akeso | 89 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Henan Cancer Hospital | Zhengzhou | China | 57 |
| Hunan Cancer Hospital | Changsha | China | 123 |
| Nanfang Hospital, Southern Medical University | Guangzhou | China | 83 |
| Shandong Cancer Hospital | Jinan | China | 86 |
| The First Hospital of Beijing University | Beijing | China | 1 |